Relay Therapeutics points to drug price negotiations for delay in potential blockbuster cancer drug
13 Oct 2023
While it may ultimately be impossible to verify why exactly a clinical-stage biotech would delay a potential new drug approval, Relay Therapeutics said yesterday that it will push back seeking approval for its potential FGFR2 selective inhibitor RLY-4008 (lirafugratinib) in bile duct cancer to wait for a larger indication because of incoming government drug price negotiations.
The decision comes as the company also announced yesterday promising new data for lirafugratinib in patients with FGFR2-altered solid tumorsFGFR2-altered solid tumors, demonstrating activity across several sub-groups, including patients with FGFR2-fusion tumors and patients with FGFR2-altered HR+/HER2- breast cancer, the company said.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.